PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1980650
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1980650
Hunter Syndrome Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of Hunter syndrome treatment Market
The global Hunter syndrome treatment market was valued at USD 1.05 billion in 2025 and is projected to grow to USD 1.12 billion in 2026, reaching USD 1.81 billion by 2034, registering a CAGR of 6.20% during 2026-2034.
North America dominated the global market with a 50.84% market share in 2025, supported by strong reimbursement frameworks, higher diagnosis rates, and the presence of major biopharmaceutical players.
Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a rare inherited lysosomal storage disorder caused by the body's inability to break down mucopolysaccharides. The disease primarily affects males and can significantly shorten life expectancy if untreated. Increasing R&D investments and clinical trials targeting neurological complications are shaping market expansion.
Market Trends
Rising R&D Investments in Rare Diseases
A significant trend influencing the market is the growing investment in orphan drug research. Several clinical-stage biotechnology companies are developing advanced therapies, including gene therapies and brain-penetrant enzyme treatments.
Companies such as:
- ArmaGen
- REGENXBIO Inc.
- Denali Therapeutics
are actively advancing pipeline candidates.
Rare diseases often receive regulatory advantages such as faster approvals and market exclusivity. Compared to traditional chronic diseases like diabetes or coronary artery disease, orphan drug approvals require smaller outcome studies, making the segment attractive for innovation.
Market Drivers
1. Unmet Clinical Needs
Currently, only two approved therapies dominate the market:
- Elaprase
- Hunterase
Elaprase remains the primary treatment globally but is expensive and inaccessible to many patients in emerging economies. Hunterase is approved in select countries but also remains costly.
Additionally, current enzyme replacement therapies (ERTs) cannot cross the blood-brain barrier, leaving neurological symptoms untreated. Approximately two-thirds of patients suffer severe neurological complications, creating demand for next-generation therapies capable of addressing central nervous system involvement.
2. Strong Pipeline Presence
According to the Genetic and Rare Diseases Information Center (GARD), nearly 7,000 rare diseases affect 25-30 million individuals in the U.S. This has accelerated R&D in rare disorders like MPS II.
Pipeline expansion and growing clinical trial activity are expected to drive substantial market growth through 2034.
Market Restraints
High Treatment Costs & Low Access in Emerging Markets
The major restraint remains the high cost of enzyme replacement therapies. In many emerging countries, reimbursement support is limited, awareness is low, and treatment access remains inadequate. As a result, a large proportion of diagnosed patients remain untreated.
Segmentation Analysis
By Treatment
The market is segmented into:
- Enzyme Replacement Therapy (ERT)
- Others (Gene therapy, HSCT, emerging modalities)
ERT dominated the market and is projected to account for 93.38% share in 2026. Both Elaprase and Hunterase are ERTs, maintaining segment leadership.
The "Others" segment is expected to grow at a higher CAGR due to advancements in gene therapy and hematopoietic stem cell transplant (HSCT).
By Route of Administration
- Intravenous
- Intracerebroventricular (ICV)/Intrathecal
The intravenous segment is expected to hold 97.46% market share in 2026, primarily due to Elaprase's intravenous administration route.
By End User
- Hospitals
- Specialty Clinics
- Others
Hospitals are projected to hold 61.70% market share in 2026, as intravenous ERT administration requires specialized medical supervision.
Regional Analysis
North America
North America recorded USD 0.54 billion in 2025 and USD 0.57 billion in 2026. The region led the market due to high diagnosis rates, strong reimbursement systems, and active clinical pipelines.
The U.S. market alone is expected to reach USD 0.53 billion by 2026.
Asia Pacific
Asia Pacific is projected to register a higher CAGR during the forecast period. Japan benefits from Hunterase availability, while China and India represent underpenetrated markets.
By 2026:
- Japan: USD 0.10 billion
- China: USD 0.03 billion
- India: USD 0.07 billion
Europe
Europe is expected to witness steady growth due to favorable rare disease policies and increasing adoption of advanced therapies.
Competitive Landscape
The market remains largely monopolistic, dominated by:
- Shire (now part of Takeda Pharmaceutical Company Limited)
Elaprase's strong clinical performance and global approval maintain Takeda's leading position.
Other key companies include:
- JCR Pharmaceuticals Co., Ltd.
- Green Cross Corp.
- CANbridge Life Sciences Ltd.
- Sangamo Therapeutics
- Inventiva
Key Industry Developments
- July 2021 - Denali Therapeutics announced positive clinical data for ETV:IDS, a brain-penetrant enzyme therapy.
- May 2021 - Inventiva presented updates on oral small molecule therapies for MPS disorders.
- March 2018 - Shire partnered with NanoMedSyn to explore advanced enzyme replacement therapies.
Conclusion
The global Hunter syndrome treatment market is poised for steady growth from USD 1.05 billion in 2025 to USD 1.81 billion by 2034, driven by increasing R&D investments, unmet neurological treatment needs, and expanding orphan drug pipelines. While high therapy costs and limited access in emerging economies remain major restraints, innovation in gene therapy and brain-penetrant treatments is expected to transform the competitive landscape.
Segmentation By Treatment
- Enzyme Replacement Therapy (ERT)
- Others
By Route of Administration
- Intravenous
- Intracerebroventricular (ICV)/ Intrathecal
By End User
- Hospitals
- Specialty Clinics
- Others
By Geography
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
- Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
- Rest of the World
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Pipeline Analysis
- 4.2. Key Industry Developments
- 4.3. Regulatory Scenario by Key Regions
- 4.4. Overview of Emerging Treatments for Hunter Syndrome
- 4.5. Reimbursement Scenario by Key Regions
5. Global Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast - By Treatment
- 5.2.1. Enzyme Replacement Therapy (ERT)
- 5.2.2. Others
- 5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Intravenous
- 5.3.2. Intracerebroventricular (ICV)/ Intrathecal
- 5.4. Market Analysis, Insights and Forecast - By End User
- 5.4.1. Hospitals
- 5.4.2. Specialty Clinics
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Rest of the World
6. North America Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Key Findings / Summary
- 6.2. Market Analysis - By Treatment
- 6.2.1. Enzyme Replacement Therapy (ERT)
- 6.2.2. Others
- 6.3. Market Analysis - By Route of Administration
- 6.3.1. Intravenous
- 6.3.2. Intracerebroventricular (ICV)/ Intrathecal
- 6.4. Market Analysis - By End User
- 6.4.1. Hospitals
- 6.4.2. Specialty Clinics
- 6.4.3. Others
- 6.5. Market Analysis - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Key Findings / Summary
- 7.2. Market Analysis - By Treatment
- 7.2.1. Enzyme Replacement Therapy (ERT)
- 7.2.2. Others
- 7.3. Market Analysis - By Route of Administration
- 7.3.1. Intravenous
- 7.3.2. Intracerebroventricular (ICV)/ Intrathecal
- 7.4. Market Analysis - By End User
- 7.4.1. Hospitals
- 7.4.2. Specialty Clinics
- 7.4.3. Others
- 7.5. Market Analysis - By Country/ sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Rest of Europe
8. Asia pacific Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Key Findings / Summary
- 8.2. Market Analysis - By Treatment
- 8.2.1. Enzyme Replacement Therapy (ERT)
- 8.2.2. Others
- 8.3. Market Analysis - By Route of Administration
- 8.3.1. Intravenous
- 8.3.2. Intracerebroventricular (ICV)/ Intrathecal
- 8.4. Market Analysis - By End User
- 8.4.1. Hospitals
- 8.4.2. Specialty Clinics
- 8.4.3. Others
- 8.5. Market Analysis - By Country/ sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. South Korea
- 8.5.5. Rest of Asia Pacific
9. Rest of the World Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Key Findings / Summary
- 9.2. Market Analysis - By Treatment
- 9.2.1. Enzyme Replacement Therapy (ERT)
- 9.2.2. Others
- 9.3. Market Analysis - By Route of Administration
- 9.3.1. Intravenous
- 9.3.2. Intracerebroventricular (ICV)/ Intrathecal
- 9.4. Market Analysis - By End User
- 9.4.1. Hospitals
- 9.4.2. Specialty Clinics
- 9.4.3. Others
10. Competitive Analysis
- 10.1. Key Industry Developments
- 10.2. Global Market Share Analysis (2017)
- 10.3. Competition Dashboard
- 10.4. Comparative Analysis - Major Players
- 10.5. Company Profiles
- 10.5.1. Shire (Takeda Pharmaceutical Company Limited)
- 10.5.1.1. Overview,
- 10.5.1.2. Products & services,
- 10.5.1.3. SWOT analysis,
- 10.5.1.4. Recent developments,
- 10.5.1.5. strategies,
- 10.5.1.6. financials (based on availability)
- 10.5.2. Denali Therapeutics
- 10.5.2.1. Overview,
- 10.5.2.2. Products & services,
- 10.5.2.3. SWOT analysis,
- 10.5.2.4. Recent developments,
- 10.5.2.5. strategies,
- 10.5.2.6. financials (based on availability)
- 10.5.3. ArmaGen
- 10.5.3.1. Overview,
- 10.5.3.2. Products & services,
- 10.5.3.3. SWOT analysis,
- 10.5.3.4. Recent developments,
- 10.5.3.5. strategies,
- 10.5.3.6. financials (based on availability)
- 10.5.4. Inventiva
- 10.5.4.1. Overview,
- 10.5.4.2. Products & services,
- 10.5.4.3. SWOT analysis,
- 10.5.4.4. Recent developments,
- 10.5.4.5. strategies,
- 10.5.4.6. financials (based on availability)
- 10.5.5. Green Cross Corp. (GC Pharma)
- 10.5.5.1. Overview,
- 10.5.5.2. Products & services,
- 10.5.5.3. SWOT analysis,
- 10.5.5.4. Recent developments,
- 10.5.5.5. strategies,
- 10.5.5.6. financials (based on availability)
- 10.5.6. CANbridge Life Sciences Ltd.
- 10.5.6.1. Overview,
- 10.5.6.2. Products & services,
- 10.5.6.3. SWOT analysis,
- 10.5.6.4. Recent developments,
- 10.5.6.5. strategies,
- 10.5.6.6. financials (based on availability)
- 10.5.7. JCR Pharmaceuticals Co., Ltd.
- 10.5.7.1. Overview,
- 10.5.7.2. Products & services,
- 10.5.7.3. SWOT analysis,
- 10.5.7.4. Recent developments,
- 10.5.7.5. strategies,
- 10.5.7.6. financials (based on availability)
- 10.5.8. REGENXBIO Inc.
- 10.5.8.1. Overview,
- 10.5.8.2. Products & services,
- 10.5.8.3. SWOT analysis,
- 10.5.8.4. Recent developments,
- 10.5.8.5. strategies,
- 10.5.8.6. financials (based on availability)
- 10.5.9. Sangamo Therapeutics
- 10.5.9.1. Overview,
- 10.5.9.2. Products & services,
- 10.5.9.3. SWOT analysis,
- 10.5.9.4. Recent developments,
- 10.5.9.5. strategies,
- 10.5.9.6. financials (based on availability)
- 10.5.1. Shire (Takeda Pharmaceutical Company Limited)
11. Strategic Recommendation
List of Tables
- Table 1: Global Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 2: Global Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 3: Global Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 4: Global Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
- Table 5: North America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 6: North America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 7: North America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 8: North America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
- Table 9: Europe Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 10: Europe Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 11: Europe Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 12: Europe Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 13: Asia Pacific Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 14: Asia Pacific Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 15: Asia Pacific Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 16: Asia Pacific Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 17: Latin America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 18: Latin America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 19: Latin America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 20: Latin America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Middle East & Africa Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 22: Middle East & Africa Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 23: Middle East & Africa Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
- Table 24: Middle East & Africa Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Hunter Syndrome Treatment Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
- Figure 2: Global Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025 & 2034
- Figure 3: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Enzyme Replacement Therapy (ERT), 2021-2034
- Figure 4: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Others, 2021-2034
- Figure 5: Global Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 6: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Intravenous, 2021-2034
- Figure 7: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Intracerebroventricular (ICV)/ Intrathecal, 2021-2034
- Figure 8: Global Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025 & 2034
- Figure 9: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Hospitals, 2021-2034
- Figure 10: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Specialty Clinics, 2021-2034
- Figure 11: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Others, 2021-2034
- Figure 12: Global Hunter Syndrome Treatment Market Value (US$ Mn), by Region, 2025 & 2034
- Figure 13: North America Hunter Syndrome Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
- Figure 14: North America Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025
- Figure 15: North America Hunter Syndrome Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
- Figure 16: North America Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 17: North America Hunter Syndrome Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
- Figure 18: North America Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025
- Figure 19: North America Hunter Syndrome Treatment Market Value (US$ Mn), By Country, 2025 & 2034
- Figure 20: North America Hunter Syndrome Treatment Market Value Share (%), By Country, 2025
- Figure 21: Europe Hunter Syndrome Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
- Figure 22: Europe Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025
- Figure 23: Europe Hunter Syndrome Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
- Figure 24: Europe Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 25: Europe Hunter Syndrome Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
- Figure 26: Europe Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025
- Figure 27: Europe Hunter Syndrome Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 28: Europe Hunter Syndrome Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 29: Asia Pacific Hunter Syndrome Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
- Figure 30: Asia Pacific Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025
- Figure 31: Asia Pacific Hunter Syndrome Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
- Figure 32: Asia Pacific Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 33: Asia Pacific Hunter Syndrome Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
- Figure 34: Asia Pacific Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025
- Figure 35: Asia Pacific Hunter Syndrome Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 36: Asia Pacific Hunter Syndrome Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 37: Latin America Hunter Syndrome Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
- Figure 38: Latin America Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025
- Figure 39: Latin America Hunter Syndrome Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
- Figure 40: Latin America Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 41: Latin America Hunter Syndrome Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
- Figure 42: Latin America Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025
- Figure 43: Latin America Hunter Syndrome Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 44: Latin America Hunter Syndrome Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 45: Middle East & Africa Hunter Syndrome Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
- Figure 46: Middle East & Africa Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025
- Figure 47: Middle East & Africa Hunter Syndrome Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
- Figure 48: Middle East & Africa Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025
- Figure 49: Middle East & Africa Hunter Syndrome Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
- Figure 50: Middle East & Africa Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025
- Figure 51: Middle East & Africa Hunter Syndrome Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 52: Middle East & Africa Hunter Syndrome Treatment Market Value Share (%), By Country/ Sub-region, 2025
- Figure 53: Global Hunter Syndrome Treatment Market Share (%), By Company, 2025
